Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision to declare the Wegovy shortage over. Eli Lilly did the same in a parallel case over Zepbound’s removal from the FDA shortage list and this week a judge denied

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday.

Wall Street's major averages dipped for the week as investors wrestled with tariff twists from the Trump administration. The S&P 500 Health Care Index Sector (XLV) was also down 0.29% during the week.

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out. | A Texas court has rejected a request by compounders to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out.

One of the few drug developers based in Worcester is leaving Wormtown for Waltham. Also, Novo Nordisk and Eli Lilly have struck partnerships with Cambridge biotechs.

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The stock is up by about 191% over the past five years compared to a 94% gain from the benchmark S&P 500 index.